Dermata Therapeutics (DRMAW) Competitors $0.01 0.00 (-6.12%) (As of 12/26/2024 05:22 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends DRMAW vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ALVO, ACABW, ACABU, BFRIW, and BTMDWShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Alvotech (ALVO), Atlantic Coastal Acquisition Corp. II (ACABW), Atlantic Coastal Acquisition Corp. II (ACABU), Biofrontera (BFRIW), and biote (BTMDW). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Alvotech Atlantic Coastal Acquisition Corp. II Atlantic Coastal Acquisition Corp. II Biofrontera biote 180 Life Sciences (NASDAQ:ATNFW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment. Is ATNFW or DRMAW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Dermata Therapeutics N/A N/A N/A Does the MarketBeat Community favor ATNFW or DRMAW? 180 Life Sciences and Dermata Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/ADermata TherapeuticsN/AN/A Which has better earnings and valuation, ATNFW or DRMAW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ADermata TherapeuticsN/AN/AN/AN/AN/A Does the media prefer ATNFW or DRMAW? In the previous week, 180 Life Sciences had 3 more articles in the media than Dermata Therapeutics. MarketBeat recorded 3 mentions for 180 Life Sciences and 0 mentions for Dermata Therapeutics. 180 Life Sciences' average media sentiment score of 1.87 beat Dermata Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive Dermata Therapeutics Neutral Summary180 Life Sciences beats Dermata Therapeutics on 2 of the 2 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMAW vs. The Competition Export to ExcelMetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$172.58M$5.23B$9.26BDividend YieldN/A3.64%5.11%4.26%P/E RatioN/A114.5187.1817.33Price / SalesN/A19,303.891,150.37123.89Price / CashN/A13.0143.2337.88Price / BookN/A8.704.895.06Net IncomeN/A-$20.89M$120.15M$225.13M7 Day PerformanceN/A0.29%3.00%4.21%1 Month PerformanceN/A223.67%17.65%3.06%1 Year PerformanceN/A140.65%28.21%17.91% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMAWDermata TherapeuticsN/A$0.01-6.1%N/A+38.0%$0.00N/A0.008ATNFW180 Life SciencesN/A$0.01flatN/A+96.0%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522,000.000.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.03flatN/A+42.2%$0.00N/A0.002AIMDWAinosN/A$0.03flatN/A-83.9%$0.00$40,633.000.0040Positive NewsALVOWAlvotechN/A$2.78+1.1%N/A+37.7%$0.00$391.87M0.004Short Interest ↓Gap UpALVOAlvotech2.43 of 5 stars$12.05+2.1%$18.00+49.4%+12.1%$0.00$93.38M0.001,026Short Interest ↑ACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03flatN/A+497.0%$0.00N/A0.004ACABUAtlantic Coastal Acquisition Corp. IIN/A$8.05-26.8%N/A-23.6%$0.00N/A0.004Gap DownBFRIWBiofronteraN/A$0.09flatN/A+325.5%$0.00$35.36M0.0070Positive NewsBTMDWbioteN/A$0.47flatN/AN/A$0.00$193.06M0.00N/A Related Companies and Tools Related Companies ATNFW Competitors LBPSW Competitors AEHAW Competitors AIMDW Competitors ALVOW Competitors ALVO Competitors ACABW Competitors ACABU Competitors BFRIW Competitors BTMDW Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRMAW) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
